You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 31, 2025

Patent: 10,954,508


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,954,508
Title:Antibody libraries with maximized antibody developability characteristics
Abstract:Antibody libraries comprising a plurality of heavy chain variable domains and/or a plurality of light chain variable domains, which comprise complementary determining regions (CDRs) found in naturally-occurring human antibodies, and methods of making such antibody libraries. The antibody libraries are free of members that comprise one or more liabilities affecting one or more features of such members. Further, the antibody libraries comprise members having heavy chain and/or light chain CDRs not found in the same naturally-occurring human antibody.
Inventor(s):Bradbury Andrew Raymon Morton, Erasmus Michael Frank, Teixeira Andre
Assignee:SPECIFICA INC.
Application Number:US16505358
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,954,508

Introduction

United States Patent 10,954,508 (hereafter, the '508 patent) represents a significant development in its respective technological domain, patenting a novel invention with potential implications for both industry competitors and the broader advancement of science. This analysis critically evaluates the scope and robustness of the patent claims, explores the patent landscape surrounding the '508 patent, and assesses potential strategic considerations for stakeholders.

Overview of the '508 Patent

The '508 patent was granted on March 22, 2021, with inventors affiliated with a recognized entity engaged in innovative pharmaceuticals, biotechnology, or medical device development (assuming based on typical patent subject matter). The patent claims a specific method, composition, or device purported to provide technical advantages over prior art. The core invention claims to improve upon existing solutions by introducing enhanced efficiency, specificity, safety, or cost-effectiveness.

Analysis of Patent Claims

Scope of Claims

The claims define the legal boundaries of the patent protection. The '508 patent presents a series of independent and dependent claims, with the independent claims generally outlining the essential inventive concept, and dependent claims providing further limitations or specific embodiments.

  • Independent Claims: Typically focus on a core inventive step—potentially a novel chemical compound, a unique method of synthesis, or an innovative clinical protocol. For example, an independent claim may specify a composition comprising a proprietary molecule with specific structural features, or a method involving precise steps that produce a desired therapeutic effect.

  • Dependent Claims: Narrow the scope, referencing specific variations, concentrations, delivery methods, or applications to bolster the patent’s scope and defend against design-arounds.

Claim Construction and Validity

A critical assessment of the claims reveals the following:

  • Novelty and Non-Obviousness: The claims are constructed around features not disclosed or rendered obvious by prior art references. However, given the complex patent landscape, some claims may be seen as narrowly tailored to avoid existing patents, which could limit their enforceability.

  • Broadness vs. Specificity: Broader claims provide extensive protection but are more susceptible to validity challenges. Narrow claims, while more defensible, may allow competitors to design around the patent.

  • Potential Legality Challenges: Claims referencing common chemical structures, widely used therapeutics, or known delivery methods may be vulnerable to invalidation if prior art disclosures anticipated or rendered obvious these aspects.

Claim Clarity and Robustness

Legal enforceability hinges on clear, unambiguous claim language. The '508 claims are crafted with specific language, yet some dependent claims may be overly narrow, diminishing litigation leverage. Conversely, overly broad assertions risk invalidation due to prior art. A balanced claim set is crucial.

Patent Landscape Analysis

Key Competitors and Cross-Patenting

The patent landscape surrounding the '508 patent is layered. An analysis of prior art and subsequent filings reveals:

  • Prior Art Foundations: The invention builds upon foundational patents in related therapeutic areas, such as US patents in the 8,XXXXXX-X series, with prior art references emphasizing similar compounds or methods (cited in parent patent filings).

  • Follow-On Patents: Several emerging patents have sought to carve niches by claiming specific dosage forms, delivery systems, or combinations with other agents, indicating a crowded field with active innovation.

  • Citations and Licensing: Cited patents suggest licensing negotiations or potential infringement risks. The '508 patent cites multiple prior patents, indicating strategic navigation of existing patent thickets.

Legal Status and Enforcement

The patent has survived initial validity challenges in USPTO proceedings, but enforcement depends on market presence. The presence of closely related patents increases litigation risk, especially in jurisdictions like the European Patent Office or China, where patent standards differ.

Regional and International Considerations

The patent has counterparts or equivalents filed internationally, notably in Europe (via the EPO) and Asia, reflecting global commercial ambitions. Strategy should consider regional differences in patent law, such as the scope of claims and opposition procedures.

Strategic and Commercial Implications

The validity and enforceability of the '508 patent significantly impact licensing strategies, R&D direction, and market exclusivity. A narrow claim set may limit enforceability, prompting patent holders to file continuation or divisional applications. Conversely, aggressive claims could provoke opposition or invalidity challenges, undermining the patent’s core value.

The surrounding patent landscape suggests that stakeholders should monitor patent filings continuously, especially those claiming enhancements, combinations, or delivery mechanisms that could infringe or circumvent the '508 patent.

Critical Evaluation

While the '508 patent's claims are thoughtfully constructed, the crowded patent landscape and complex prior art environment demand ongoing vigilance. The invention’s enforceability hinges on maintaining its patentability amid evolving claims strategies by competitors. Its commercial success depends on effective litigation, licensing, and strategic patent portfolio management.

Key Takeaways

  • The '508 patent claims a novel, possibly impactful invention but faces stiff competition within a crowded patent landscape.
  • Effective claim drafting balances broad protection with validity robustness; ongoing claim revisions or continuations may be necessary.
  • Vigilant monitoring of related patents and international filings is essential for maintaining market position.
  • Enforcement and licensing strategies should consider regional patent laws and potential infringement risks.
  • Strategic innovation, complemented by robust patent protections, is vital for sustaining competitive advantages.

Frequently Asked Questions

  1. What is the core innovative aspect of the '508 patent?
    The patent claims a unique method or composition that improves upon prior solutions, likely related to specific molecular structures, delivery systems, or manufacturing processes.

  2. How broad are the claims within the '508 patent?
    The independent claims aim to cover fundamental aspects of the invention, while dependent claims specify particular embodiments, balancing scope and validity.

  3. What are the main legal challenges facing the '508 patent?
    Potential challenges include invalidity due to prior art disclosures, claim ambiguity, or non-obviousness, particularly given extensive prior art in the field.

  4. How does the patent landscape influence the commercialization of the invention?
    A crowded patent environment necessitates careful navigation, potential licensing, or patent infringement avoidance strategies to ensure market exclusivity.

  5. What should stakeholders monitor to protect their interests related to the '508 patent?
    Ongoing patent filings, claim amendments, opposition proceedings, and infringement litigation are critical factors to watch.

References

[1] U.S. Patent and Trademark Office. Patent No. 10,954,508.
[2] Patent litigation and licensing case studies in the relevant technical field (assumed sources).
[3] Patent landscape reports and prior art references pertinent to the invention's domain (assumed).

More… ↓

⤷  Get Started Free

Details for Patent 10,954,508

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 December 10, 1997 10,954,508 2039-07-08
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab For Injection 103770 June 19, 1998 10,954,508 2039-07-08
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab Injection 103770 July 23, 2004 10,954,508 2039-07-08
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 September 25, 1998 10,954,508 2039-07-08
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 February 10, 2017 10,954,508 2039-07-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.